BioPharma Dive 24 mars 2026 Gilead, with Ouro deal, wagers $1.7B on bispecifics for autoimmune diseases
BioPharma Dive 24 mars 2026 How former Acorda CEO Ron Cohen landed at a Parkinson’s cell therapy startup
BioPharma Dive 23 mars 2026 Pfizer, Valneva to seek approval of Lyme disease vaccine despite mixed study results
BioPharma Dive 23 mars 2026 FDA seeks feedback on voucher program; Study data lift ‘overhang’ on Insmed shares